Half-year Financial Report

Summary by AI BETAClose X

Biotech Growth Trust reported unaudited results for the six months to 30 September 2026: NAV per share rose 14.8% to 1,623.8p (from 1,414.6p) and the share price rose 22.9% to 1,548.0p (from 1,260.0p) versus a NASDAQ Biotechnology Index gain of 21.6%; the share discount narrowed from 10.9% to 4.7%. The Company reduced gearing to nil and held net cash of 5.2% at period end, completed buybacks of 1,114,074 shares at an average 9.0% discount costing £15.7m (5.6% of starting shares) which added 0.5% to NAV, recorded ongoing charges of 1.2%, saw five holdings announced for acquisition and top contributors added c.142.7p while detractors subtracted c.54.5p per share.

Disclaimer*

UK 100

Latest directors dealings